EMEA-003214-PIP01-22
Key facts
| Active substance |
Humanized monoclonal antibody of IgG1 subtype targeting NRP1
|
| Therapeutic area |
Ophthalmology
|
| Decision number |
P/0283/2022
|
| PIP number |
EMEA-003214-PIP01-22
|
| Pharmaceutical form(s) |
Solution for injection
|
| Condition(s) / indication(s) |
Treatment of diabetic retinopathy
|
| Route(s) of administration |
Intravitreal use
|
| Contact for public enquiries |
Boehringer Ingelheim International GmbH
E-mail: COMMSPaediatrics@boehringer-ingelheim.com |
| Decision type |
W: decision granting a waiver in all age groups for all conditions or indications
|